Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05462379
Other study ID # NP1782
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 8, 2022
Est. completion date June 8, 2024

Study information

Verified date March 2024
Source Instituto do Cancer do Estado de São Paulo
Contact Marilia Bertolazzi, MD
Phone 5519989172189
Email marilia.bertolazzi@hc.fm.usp.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pelvic chemoradiotherapy (CRT) is an effective treatment for Locally Advanced Cervical Cancer (LACC). However, CRT induces premature ovarian failure ceasing the production of ovarian hormones. This may lead to severe consequences to the patient's life quality, sexuality and overall healthy. An acceptable treatment to minimize the adverse effects caused by the lack of ovarian hormones is hormonal replacement but less than 40% of the patients younger than 50 years have access to this treatment. A second alternative treatment is ovarian transposing which is a surgical technique with variable success rate depending on how far the ovaries are from the radiotherapy field. A third, more promising, alternative is involves using autologous ovarian tissue as a graft in tissues far from the radiotherapy field. This treatment has the potential of maintaining the natural ovarian hormones production at a lower-cost and requiring a simpler procedure. The primary objective of this randomized phase 1-2 clinical trial is to validate the feasibility of ovarian tissue engraft into fatty tissue and its endocrine functionality.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date June 8, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Pathologic diagnosis of squamous cell carcinoma or adenocarcinoma of the cervix. - FIGO 2018 staging IB3 to IVA. - Absence of ovarian involvement. - Age =35 Years. - Absence of metastatic disease. - Written consent. Exclusion Criteria: - Previous treatment for cervical cancer or other malignant diseases. - Rare histology tumors. - Absence of one or both ovaries.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Ovarian graft
Before the beginning of pelvic radiotherapy, one of the ovaries will be removed by laparoscopy. Ovary slices of 1-2 mm will be prepared in sterile environment and engrafted in the fatty tissue of inner tight. One representative fragment will undergo histologic evaluation. These procedures will be done in the same surgical time.

Locations

Country Name City State
Brazil Instituto do Cancer do Estado de São Paulo São Paulo

Sponsors (1)

Lead Sponsor Collaborator
MARILIA ALBANEZI BERTOLAZZI

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dosage of serum levels of follicle stimulating hormone (FSH) in mUI/ml in intervention (engraft of ovarian tissue into fatty tissue) and control groups. Dosage will be performed at baseline and post radiotherapy (2, 6, 12 and 24 months). Endocrine functionality is defined as FSH levels under 25 mUI/ml. 2 years
Primary Dosage of serum levels of estradiol in pg/ml in intervention (engraft of ovarian tissue into fatty tissue) and control groups. . Dosage will be performed at baseline and post radiotherapy (2, 6, 12 and 24 months). Endocrine functionality is defined as estradiol upper 47 pg/mL. 2 years
Secondary Dosage of serum levels of glucose in mg/dL in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24). Evaluation of glucose metabolism. 2 years
Secondary Measure of serum glycated hemoglobin in percentage in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24). Evaluation of glucose metabolism. 2 years
Secondary Measure of serum levels of cholesterol in mg/dL in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24). Evaluation of lipid metabolism. 2 years
Secondary Measure of serum levels of triglycerides in mg/dL in intervention and control groups. (Time frame: At baseline and post radiotherapy month 2, 6, 12 and 24). Evaluation of lipid metabolism. 2 years
Secondary Evaluate the changes in bone mineral density (BMD) in femoral neck and lumbar spine by bone densitometry, evaluating T and Z scores standard deviation (SD) in intervention and control groups. Time frame: At baseline and post radiotherapy month 12 and 24. 2 years
Secondary Bioimpedance monitoring to evaluate changes in body composition by fat and lean mass percentage in intervention and control groups. Time frame: At baseline and post radiotherapy month 12 and 24). 2 years
Secondary Quantification of body mass index reported in kg/m2 in intervention and control groups. Time frame: At baseline and post radiotherapy month 12 and 24). Evaluation of changes in body mass. 2 years
Secondary Score life quality in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) in intervention and control groups. EORTC QLQ C30 was developed and validated to assess the quality of life of cancer patients.
The 30-item EORTC QLQ-C30 is a disease-specific measure that assesses multiple QoL domains in patients with cancer. There are five functioning scales that measure physical, role, emotional, cognitive, and social functioning. Three symptom scales measure fatigue, pain, and nausea/vomiting.
2 years
Secondary Score life quality in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Cervical Cancer Module (EORTC QLQ C30 CX24) in intervention and control groups. EORTC QLQ-CX24 Scoring Manual The Cervical Cancer Module is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30. The EORTC QLQ-CX24 was designed to assess disease-specific and treatment-specific aspects of QoL in patients with cervical cancer. 2 years
See also
  Status Clinical Trial Phase
Unknown status NCT01853501 - Effects of ADSC Therapy in Women With POF Phase 4
Completed NCT00417066 - Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Phase 4
Active, not recruiting NCT04675970 - Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
Recruiting NCT03480412 - Second Step Protocol in Poor Ovarian Responder (POR)
Completed NCT02644447 - Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF Phase 1/Phase 2
Completed NCT03840824 - Blood Spot Self-administered Test and Assay
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06117982 - The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency Phase 2
Suspended NCT03816852 - The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency Phase 2
Not yet recruiting NCT04390308 - Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?
Completed NCT02783937 - Filgrastim for Premature Ovarian Insufficiency Phase 4
Completed NCT00295087 - X-Chromosome Inactivation Status and Premature Ovarian Failure N/A
Completed NCT00429494 - GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Phase 2
Not yet recruiting NCT05522634 - A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency Early Phase 1
Recruiting NCT05838157 - The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
Withdrawn NCT01129947 - The Use of DHEA in Women With Premature Ovarian Failure Phase 0
Completed NCT00001275 - Ovarian Follicle Function in Patients With Primary Ovarian Failure N/A
Not yet recruiting NCT04306185 - Ovarian Fragmentation Study (Crespo Medical Team) N/A
Recruiting NCT02062931 - Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Phase 1/Phase 2
Completed NCT02372474 - "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Phase 1/Phase 2